Advertisement
EXEL vs HRMY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and HRMY is a Hold.
EXEL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for EXEL turned positive on October 09, 2026. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on EXEL as a result. In 65 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
Following a +5.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in 204 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 166 of 268 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
EXEL broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.843) is normal, around the industry mean (26.782). P/E Ratio (18.355) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.305) is also within normal values, averaging (437.542).
HRMY in downward trend: 10-day moving average moved below 50-day moving average on October 08, 2026
The 10-day moving average for HRMY crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HRMY as a result. In 62 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for HRMY turned negative on September 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 28 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
HRMY moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for HRMY entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HRMY's RSI Indicator exited the oversold zone, 24 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 60 cases where HRMY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +3.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRMY advanced for three days, in 210 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
HRMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. HRMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.332) is normal, around the industry mean (26.782). P/E Ratio (12.948) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (2.581) is also within normal values, averaging (437.542).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
EXEL | HRMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 66 Overvalued | |
PROFIT vs RISK RATING 1..100 | 5 | 98 | |
SMR RATING 1..100 | 23 | 46 | |
PRICE GROWTH RATING 1..100 | 37 | 42 | |
P/E GROWTH RATING 1..100 | 45 | 13 | |
SEASONALITY SCORE 1..100 | 48 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HRMY's Valuation (66) in the null industry is in the same range as EXEL (80) in the Biotechnology industry. This means that HRMY’s stock grew similarly to EXEL’s over the last 12 months.
EXEL's Profit vs Risk Rating (5) in the Biotechnology industry is significantly better than the same rating for HRMY (98) in the null industry. This means that EXEL’s stock grew significantly faster than HRMY’s over the last 12 months.
EXEL's SMR Rating (23) in the Biotechnology industry is in the same range as HRMY (46) in the null industry. This means that EXEL’s stock grew similarly to HRMY’s over the last 12 months.
EXEL's Price Growth Rating (37) in the Biotechnology industry is in the same range as HRMY (42) in the null industry. This means that EXEL’s stock grew similarly to HRMY’s over the last 12 months.
HRMY's P/E Growth Rating (13) in the null industry is in the same range as EXEL (45) in the Biotechnology industry. This means that HRMY’s stock grew similarly to EXEL’s over the last 12 months.
| EXEL | HRMY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 65% | 1 day ago 77% |
| Stochastic ODDS (%) | 1 day ago 51% | 1 day ago 77% |
| Momentum ODDS (%) | 1 day ago 71% | 1 day ago 70% |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 67% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 67% | 1 day ago 71% |
| Advances ODDS (%) | 2 days ago 67% | 2 days ago 74% |
| Declines ODDS (%) | 4 days ago 59% | 4 days ago 73% |
| BollingerBands ODDS (%) | 1 day ago 56% | 1 day ago 74% |
| Aroon ODDS (%) | 1 day ago 62% | 1 day ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EXEL’s FA Score shows that 2 FA rating(s) are green while HRMY’s FA Score has 1 green FA rating(s).
- EXEL’s FA Score: 2 green, 3 red.
- HRMY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EXEL’s TA Score shows that 4 TA indicator(s) are bullish while HRMY’s TA Score has 4 bullish TA indicator(s).
- EXEL’s TA Score: 4 bullish, 4 bearish.
- HRMY’s TA Score: 4 bullish, 6 bearish.
Price Growth
EXEL (@Biotechnology) experienced а +3.96% price change this week, while HRMY (@Biotechnology) price change was -5.78% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
Reported Earning Dates
EXEL is expected to report earnings on Nov 03, 2026.
HRMY is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Biotechnology (-10.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| USDX | 25.62 | 0.05 | +0.19% |
| SGI Enhanced Core ETF (USDX) | |||
| HYGM | 23.79 | N/A | N/A |
| Amplify HYG High Yield 10% Target Income ETF (HYGM) | |||
| XOEF | 29.49 | -0.21 | -0.71% |
| iShares S&P 500 ex S&P 100 ETF (XOEF) | |||
| DVYE | 34.96 | -0.47 | -1.33% |
| iShares Emerging Markets Dividend ETF (DVYE) | |||
| APLX | 3.56 | -1.08 | -23.28% |
| Tradr 2X Long APLD Daily ETF (APLX) | |||
HRMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with EXEL. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then EXEL could also see price increases.
| Ticker / NAME | Correlation To HRMY | 1D Price Change % | ||
|---|---|---|---|---|
| HRMY | 100% | -0.84% | ||
| EXEL - HRMY | 34% Loosely correlated | -0.95% | ||
| AXON - HRMY | 31% Poorly correlated | -6.45% | ||
| MDGL - HRMY | 31% Poorly correlated | -2.19% | ||
| INCY - HRMY | 31% Poorly correlated | -0.18% | ||
| ORMP - HRMY | 30% Poorly correlated | -2.63% | ||
More | ||||